Surrogate Markers and its role in the Drug Development Process Aloka G. Chakravarty, Ph.D. Director, Biologics Therapeutics Statistical Staff [email protected].
New Paradigms for Clinical Drug Development in the Genomic Era Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute .
FDA-Industry-Biomarkers.ppt
Transforming Correlative Science to Predictive Personalized Medicine Richard Simon, D.Sc. National Cancer Institute .
Using Predictive Biomarkers in the Design of Adaptive Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Predictive Biomarkers and Their Use in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute .
